Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study developed a new synthetic route for finasteride that omits the costly reagent 2,2′ dipyridyl disulfide, achieving an overall yield of 16%.

This abstract reports that topical minoxidil is currently the only FDA-approved treatment for pattern hair loss in both men and women.

This study found that antroquinonol inhibited CD8+ T cell proliferation and reduced proinflammatory cytokine secretion in vitro, while also ameliorating H2O2-induced depigmentation and resisting reductions in hair follicle length, skin thickness, and tyrosinase expression in mice.

This study found that a new formulation kit of Pielus Anti-hair loss lotion and shampoo, used daily for 90 days, was safe and effective in reducing hair loss and increasing hair strength and density among patients with telogen effluvium and/or androgenetic alopecia.

This review summarizes therapeutic advances reported in English-language literature from December 1987 to December 1988 and states no new clinical results.

The new compounds may be more effective and cheaper than current treatments for conditions like baldness.

This study found that both finasteride and a new steroidal compound, PM-9, competitively inhibit the 5α-reductase enzyme in Penicillium crustosum broth.

This article discusses the potential use of 5α-reductase inhibitors in dermatology and reports no new clinical results; the authors suggest further exploration of their dermatological applications.

This study reported that newly synthesized nonsteroidal compounds were effective at inhibiting prostatic 5 alpha reductase isozyme 2, especially the compound with an N, N-diisopropylcarbamoyl substituent, suggesting potential for treating benign prostatic hyperplasia.

This study reported that Cosmerna ARI significantly improved androgenetic alopecia in Europeans over a 6-month period compared to a placebo, according to a double-blind, randomized, placebo-controlled clinical trial.

This review found that 5α-reductase inhibitors are associated with slightly increased rates of sexual dysfunction, gynecomastia, and mood disorders, but the true significance and persistence of these effects remain unclear.

This study reports that novel hexahydrobenzoquinolin compounds fully inhibited 5α-reductase activity in human genital skin fibroblasts, suggesting their potential for treating conditions like benign prostatic hyperplasia and male pattern baldness.

This study found that several dehydroepiandrosterone ester derivatives effectively reduced prostate and seminal vesicle weight in gonadectomized hamsters treated with testosterone, demonstrating potential antiandrogen effects comparable to Finasteride.

This study found that deslorelin implants can effectively reduce estradiol levels and support hair regrowth in neutered ferrets with hyperoestrogenism caused by nodular hyperplasia of the adrenocortex.

This narrative review highlights the critical role of intracrine hormone production in peripheral tissues, suggesting that continuous-release subcutaneous testosterone pellet therapy may offer a more effective symptom-driven approach for aging populations, though large-scale randomized controlled trials are needed for confirmation.

In this study, the addition of a SULT1A1 enzyme booster to daily 5% minoxidil treatment significantly increased hair regrowth in men with androgenic alopecia compared to minoxidil alone.

This study found that formulating raloxifene in nano-lipid carriers significantly enhanced its permeation and cytotoxicity against cancer cells compared to raw raloxifene.

This study reports that the dye peri-xanthenoxanthene (PXX) can act as an efficient photocatalyst for various radical reactions, including complex dual catalytic processes and the synthesis of an investigational drug intermediate.

This review discusses ethosomes as potential carriers for delivering drugs into deeper skin layers and provides no new clinical results, suggesting a need for further studies on their efficiency in dermal therapies.

This study found that a new deoxycholic acid derivative may offer a similar prostatoprotective effect to finasteride with lower toxicity in rat models.

This article reviews treatment-induced sexual dysfunctions related to 5-alpha-reductase inhibitors and reports no new results; it highlights the need to better define and understand this controversial topic.

This review found that adding cyproterone acetate to estradiol showed a subjective improvement in hirsutism versus placebo, but comparisons with other therapies revealed no clinical differences.

This study found that lipids extracted from Schizochytrium sp. significantly enhanced the proliferation and survival of dermal papilla cells under oxidative stress, reduced reactive oxygen species, inhibited ferroptosis, and promoted antioxidant genes, which improved hair growth in experimental settings, suggesting a potential treatment for alopecia.

This study investigated a finasteride and oregano oil-loaded nano-cubosome gel formulation, finding it enhanced drug release and skin permeation and demonstrated synergistic antibacterial effects, suggesting potential for treating alopecia areata.

This review highlights the need for a deeper understanding of 5alpha-reductases and neuroactive steroids to reduce potential adverse effects of 5alpha-reductase inhibitors used for conditions like benign prostatic hyperplasia and androgenic alopecia, but reports no new clinical results.

This study proposes that combining trazodone and clomiphene citrate could potentially restore libido synaptic circuits and treat post-finasteride syndrome, which involves persistent sexual dysfunction after discontinuing finasteride treatment.

This review summarizes the adverse effects associated with 5α‐reductase inhibitors, noting slightly increased rates of decreased libido, erectile and ejaculatory dysfunction, gynecomastia, depression, and anxiety, with further studies needed to explore symptom prevalence and persistence.

This review discusses persistent sexual and nonsexual adverse effects of the 5α-reductase inhibitor finasteride in younger men, including erectile dysfunction, low libido, and depression. It reports no new clinical results but emphasizes further research is needed.

This study found that a proniosomal gel formulation of finasteride increased anagen hair count in male volunteers with androgenic alopecia by 42.85% compared to the control group.